Bulk Inquiry
MK 0822
- Odanacatib
Axon 1771
CAS:
603139-19-1
- Optical Purity: Optically pure
- Soluble in DMSO
- MF: C25H27F4N3O3S
- MW: 525.56
Description
MK 0822 is a potent and selective cathepsin K (CTSK/Cat K) inhibitor.
Cathepsin K is an osteoclast cysteine protease responsible for collagen degradation during bone resorption. MK 0822 (Odanacatib) is useful for studying osteoclast function, bone matrix turnover and protease-targeted osteoporosis pharmacology.
Key Features
- Potent inhibitor of cathepsin K
- Targets osteoclast collagen-degrading protease activity
- Relevant to bone resorption biology
- Selective cysteine protease pharmacology tool
Applications
- Cathepsin K enzyme assays
- Osteoclast and bone resorption studies
- Osteoporosis research models
- Protease inhibitor selectivity profiling
More Information
| Parent CAS No. | 603139-19-1 |
|---|---|
| Chemical Name | (S)-N-(1-cyanocyclopropyl)-4-fluoro-4-methyl-2-((S)-2,2,2-trifluoro-1-(4'-(methylsulfonyl)biphenyl-4-yl)ethylamino)pentanamide |
| SMILES | C1C=C([C@@H](C(F)(F)F)N[C@@H](CC(C)(C)F)C(=O)NC2(CC2)C#N)C=CC=1C1C=CC(S(=O)(=O)C)=CC=1 |&1:3,9,r| |
| MFCD | N.A. |
| InChi | InChI=1S/C25H27F4N3O3S/c1-23(2,26)14-20(22(33)32-24(15-30)12-13-24)31-21(25(27,28)29)18-6-4-16(5-7-18)17-8-10-19(11-9-17)36(3,34)35/h4-11,20-21,31H,12-14H2,1-3H3,(H,32,33)/t20-,21-/m0/s1 |
| InChiKey | FWIVDMJALNEADT-SFTDATJTSA-N |
| CID | 10152654 |
| Short Description | Cathepsin K inhibitor |
MK 0822
potent cathepsin K inhibitor
Odanacatib
MK0822
Cathepsin-K
cathepsin K
Inhibitor
Cathepsin K enzyme assays
Osteoclast and bone resorption studies
Osteoporosis research models
Protease inhibitor selectivity profiling
bone biology
receptor selectivity
enzyme pharmacology
drug discovery
CAS 603139-19-1
Axon Medchem
Axon 1771
Supplier
Vendor
References
- CL Le Gall et al. Cathepsin K inhibitors as treatment of bone metastasis. Curr. Opin. Support. Palliat. Care. 2008, 2(3), 218.
- JY Gauthier et al. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg. Med. Chem. Lett. 2008, 18(3), 923–928.
- EM Lewiecki. Odanacatib, a cathepsin K inhibitor for the treatment of osteoporosis and other skeletal disorders associated with excessive bone remodeling. IDrugs. 2009, 12(12), 799-809.
Other Categories
Get a Quote for
Loading...